# Molecular docking and dynamics studies to identify novel active compounds targeting potential breast cancer receptor proteins from an indigenous herb Euphorbia thymifolia Linn

**Authors:** Vasavi Kumblekar, Reshma Kumarchandra, K Sreedhara Ranganath Pai, ShamaPrasada K, Suman Manandhar, Rajeshwari Shastry, Sharada Rai, Renukaradhya Math, Vasavi Kumblekar

PMC · DOI: 10.12688/f1000research.146862.1 · 2024-04-25

## TL;DR

This study uses computer modeling to find compounds in a tropical herb that may target breast cancer proteins, offering potential new drug candidates.

## Contribution

The study identifies two novel phytocompounds from Euphorbia thymifolia with high binding affinity to breast cancer-related proteins using in-silico methods.

## Key findings

- TTDB showed strong binding to HER2 and ERK1 proteins with low energy.
- SADPE exhibited high affinity for the estrogen receptor (ER).
- GC-MS identified 245 phytoconstituents, 219 of which were unique.

## Abstract

Breast cancer has become the most prevalent disease and its incidence has almost doubled in the Indian population. This increased burden demands new targeted therapies with novel compounds either synthetically produced or derived from indigenous plants, which could be a promising approach for the development of drugs.
Euphorbia thymifolia L is a widely growing tropical herb that has been reported to have various ethnopharmacological properties, including anticancer properties. Therefore, the aim of the present study was to screen the phytoconstituents and identify the active compounds present in the methanolic extract of
E. thymifolia (ME.ET) as ligands to inhibit potential protein targets implicated in breast cancer using an
In-silico approach.

ME.ET was subjected to GC-MS analysis to screen the phytoconstituents, and the identified compounds were docked with protein targets such as extracellular signal-regulated kinases (ERK1), a serine/threonine kinase-1(AKT1), human epidermal growth factor 2 (HER2), estrogen receptor (ER), maternal embryonic leucine zipper kinase (MELK), polo-like kinase-1(PLK1), and protein tyrosine kinase (PTK6). Compounds with good docking scores were further subjected to dynamic studies to understand the protein ligand binding stability, ligand pathway calculation, and molecular mechanics energies combined with Poisson-Boltzmann (MM/PBSA) calculations using the Schrodinger suite.

GC-MS analysis revealed the presence of 245 phytoconstituents, 219 of which were unique. When subjected to docking, these phytocompounds, namely 3,6,9,12-tetraoxatetradecane-1,14-diyl dibenzoate (TTDB) and succinic acid, 2-(dimethylamino) ethyl 4-isopropylphenyl ester (SADPE), showed good docking scores. Molecular dynamics studies showed a high affinity and low binding energy for TTDB with HER2, ERK1, and SADPE with ER.

Hence, in this study, we identified two lead compounds in
E.thymifolia linn. Further
invitro and
invivo anticancer studies can be performed to confirm these results and to understand the molecular mechanism by which they exhibit anticancer activity against breast cancer.

## Linked entities

- **Genes:** MAPK3 (mitogen-activated protein kinase 3) [NCBI Gene 5595], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064], EREG (epiregulin) [NCBI Gene 2069], MELK (maternal embryonic leucine zipper kinase) [NCBI Gene 9833], PLK1 (polo like kinase 1) [NCBI Gene 5347], PTK6 (protein tyrosine kinase 6) [NCBI Gene 5753]
- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** PLK1 (polo like kinase 1) [NCBI Gene 5347] {aka PLK, STPK13}, MELK (maternal embryonic leucine zipper kinase) [NCBI Gene 9833] {aka HPK38}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, FGFR4 (fibroblast growth factor receptor 4) [NCBI Gene 2264] {aka CD334, JTK2, TKF}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, PTK6 (protein tyrosine kinase 6) [NCBI Gene 5753] {aka BRK}, MAPK3 (mitogen-activated protein kinase 3) [NCBI Gene 5595] {aka ERK-1, ERK1, ERT2, HS44KDAP, HUMKER1A, P44ERK1}
- **Diseases:** cancer (MESH:D009369), Breast cancer (MESH:D001943)
- **Chemicals:** succinic acid (MESH:D019802), 2-(dimethylamino) ethyl 4-isopropylphenyl ester (-)
- **Species:** Euphorbia thymifolia (gulf sandmat, species) [taxon 318061], Homo sapiens (human, species) [taxon 9606]

## Figures

12 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12199905/full.md

---
Source: https://tomesphere.com/paper/PMC12199905